Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1386]

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non...

Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation ( Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA )

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Emerging systemic therapies in rare urothelial cancer variants

Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA

Emerging systemic therapies in rare urothelial cancer variants ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )

Lenvatinib plus pembro for aRCC - update on the CLEAR study

Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA

Lenvatinib plus pembro for aRCC - update on the CLEAR study ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim...

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast...

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple...

Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer ( Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands )

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum...

Prof Siow-Ming Lee - University College London, London, UK

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen ( Prof Siow-Ming Lee - University College London, London, UK )

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in...

Prof Siow-Ming Lee - University College London, London, UK

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC ( Prof Siow-Ming Lee - University College London, London, UK )

RADICALS-HD trial: androgen deprivation therapy with post-operative...

Prof Chris Parker - Institute of Cancer Research, Sutton, UK

RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer ( Prof Chris Parker - Institute of Cancer Research, Sutton, UK )

A new era of early cancer detection with blood test may change cancer screening...

Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA

A new era of early cancer detection with blood test may change cancer screening paradigms ( Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA )

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally...

Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )

More from ecancer